Akeso
160
46
68
57
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
4.4%
7 terminated/withdrawn out of 160 trials
89.1%
+2.5% vs industry average
23%
36 trials in Phase 3/4
0%
0 of 57 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (160)
SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
Role: collaborator
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Role: lead
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Role: lead
Phase III Study of AK112 for NSCLC Patients
Role: collaborator
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
Role: lead
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Role: lead
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
Role: lead
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
Role: lead
A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects
Role: lead
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
Role: lead
A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer
Role: lead
A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma
Role: lead
Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer
Role: collaborator
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations
Role: lead
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
Role: lead
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
Role: lead
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
Role: lead
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Role: lead
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Role: lead
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Role: lead